Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ursane pentacyclic triterpenoids in preparing tumor radiotherapy sensitivity drugs

A tumor radiotherapy and compound technology, which is applied in the direction of anti-tumor drugs, drug combinations, pharmaceutical formulations, etc., can solve the problem of tumor radiotherapy resistance that is difficult to overcome, and achieve the effect of improving sensitivity

Inactive Publication Date: 2020-01-14
INST OF RADIATION MEDICINE CHINESE ACADEMY OF MEDICAL SCI
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The present invention aims at the defect that tumor cells are prone to produce radiotherapy resistance, and provides a new preparation method and application of a new ursane-type pentacyclic triterpenes-specific deSUMOylated protease 1 inhibitor compound to solve the problem of prior art The technical problem that is difficult to overcome in tumor radiotherapy resistance, the described ursane-type pentacyclic triterpenes have the following general structural formula:

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ursane pentacyclic triterpenoids in preparing tumor radiotherapy sensitivity drugs
  • Application of ursane pentacyclic triterpenoids in preparing tumor radiotherapy sensitivity drugs
  • Application of ursane pentacyclic triterpenoids in preparing tumor radiotherapy sensitivity drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 Immunoprecipitation method to determine the inhibitory activity of compounds to specific deSUMOylated protease 1

[0030] Hela cells in logarithmic growth phase were inoculated on 25cm 2 Cell culture flasks were cultured overnight; after the cells completely adhered to the wall and recovered their shape, they were replaced with the medium containing ursolic acid or the test compound at a final concentration of 5 μM, and continued to culture for 24 hours; the medium was removed, and washed with PBS for two Digest with 0.25% trypsin, collect cells by centrifugation at 1500rpm for 5min; add 200μl RIPA lysate (with protease inhibitors PMSF and aprotinin added) to each sample, lyse on ice for 1h, shake and suspend once every 15min; 4°C Centrifuge at low temperature, 14000×g for 15 minutes, carefully absorb the supernatant (avoid absorbing the precipitate). Protein quantification was performed on the recovered supernatant.

[0031] Protein quantification was perfo...

Embodiment 2

[0045] Example 2 Cytotoxicity Experiment

[0046] Hela cells in the logarithmic growth phase were divided into 3×10 4 Cells / mL were inoculated in 96-well plates, 100 μL per well, and cultured overnight. After the cells were adhered to the wall and their morphology recovered under the microscope, the original medium was sucked off, washed with D-hanks buffer, and the drug solution of the compound to be tested was added to the medium without fetal bovine serum. The final concentrations were 0.7, 2.2, 6.6, 20μM, set three replicate wells for each group, and set the corresponding blank group, add 0.1% DMSO to the control group, set three replicate holes for each group, and set the corresponding blank group; at 37°C, 5% CO 2 Continue culturing for 72 hours under the same conditions, add 10 μL of CCK-8 detection solution to each well, and continue to incubate for 1 hour in a 37° C. incubator. Use a microplate reader to read the absorbance value (A) of each well at a wavelength of ...

Embodiment 53

[0054] Example 53 clone formation experiment

[0055] Hela cells in the logarithmic growth phase were digested with 0.25% trypsin and pipetted to form a single cell, and the cell suspension was diluted to an appropriate concentration. In the experiment, 1, 18, and 22 were used as experimental groups, and 5 groups of different irradiation doses (0Gy, 2Gy, 4Gy, 6Gy, 8Gy) were set for each group. Different numbers of cells were inoculated in different irradiation dose groups, and each dose of medicine in each group was set In three parallel experimental wells, 200 cells were inoculated per well in the 0Gy group and 2Gy group, 500 cells were inoculated in each well in the 4Gy group, 2000 cells were inoculated in each well in the 6Gy group, and 5000 cells were inoculated in each well in the 8Gy group. After inoculating the cells into a 24-well plate containing 500 μL of medium, pre-warm at 37°C, vibrate in the shape of a zigzag to disperse the cells evenly, and incubate overnight t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of ursane pentacyclic triterpenoids in preparing tumor radiotherapy sensitivity drugs. A general molecular formula of the ursane pentacyclic triterpenoids is shownin a formula I. It is found for the first time that the ursane pentacyclic triterpenoids can increase the sensitivity of tumor cells to irradiation by inhibiting the activity of SUMO-specific proteases 1 (SENP1), and the ursane pentacyclic triterpenoids are expected to become new tumor radiotherapy sensitivity drugs. (Please see the description for the formula).

Description

technical field [0001] The present invention relates to a new application of an ursane-type pentacyclic triterpenoid compound, in particular to an ursane-type pentacyclic triterpenoid compound as a specific deSUMOylated protease 1 inhibitor in the preparation of tumor radiotherapy sensitization drugs use in . Background technique [0002] The following background introduction related to the present invention is used to help the understanding of the present invention, but should not be considered as the prior art of the present invention. All cited publications are incorporated by reference in full. [0003] Natural products have always been an important source for the development of anticancer drugs due to their diversity in chemical structure, wide range of sources and high safety. As a pentacyclic triterpenoid natural product with a wide range of sources, ursolic acid has been reported to have radiosensitizing and chemosensitizing activities. Qi Rongxin and others belie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/56A61K31/58A61P35/00
CPCA61K31/56A61K31/58A61P35/00
Inventor 李祎亮魏会强勾文峰段玉清宁洪鑫毕常芬侯文彬
Owner INST OF RADIATION MEDICINE CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com